FDA Letter API

Fill It Pack It Inc

Letter data

Company
Fill It Pack It Inc
Recipient
Mr. Robert L. Miller | Vice President and Co-owner | Fill It Pack It Inc | 2555 E. Del Amo Blvd. | Compton | , | CA | 90221 | United States
Issue date
2021-07-19
Posted date
Not available
FDA office
Division of Pharmaceutical Quality Operations IV
Subject
Not available
Product
Drugs
CMS ID
570946
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Fill It Pack It Inc MARCS-CMS 570946 — July 19, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Delivery Confirmation Product: Drugs Recipient: Recipient Name Mr. Robert L. Miller Recipient Title Vice President and Co-owner Fill It Pack It Inc 2555 E. Del Amo Blvd. Compton , CA 90221 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States 949-608-2900 Dear Mr. Miller: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your response to our Warning Letter (Ref CMS 570946) dated May 2, 2019. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV Content current as of: 07/21/2021 Regulated Product(s) Drugs